Skip to main content
. 2021 May 7;7(19):eabe5171. doi: 10.1126/sciadv.abe5171

Fig. 6. Activation of c-Abl by its agonist DPH facilitates c-Cbl–mediated inhibition of RelB activation to restrict DSS-induced colitis.

Fig. 6

(A and B) Immunoblotting analysis of α-mannan–induced interaction of c-Cbl and c-Abl in BMDCs without (A) or with (B) Syk inhibitor R406 pretreatment. (C and D) Immunoblotting analysis of α-mannan–induced phosphorylation of c-Cbl in wild-type BMDCs with c-Abl inhibitor (flumatinib mesylate) pretreatment (C) or knockdown of murine c-Abl (D). (E and F) Immunoblotting analysis of α-mannan–induced degradation of RelB in BMDCs with flumatinib mesylate pretreatment (E) or knockdown of murine c-Abl (F). (G) Immunoblotting analysis of α-mannan–induced nuclear translocation of RelB and p65 in BMDCs with flumatinib mesylate pretreatment. (H and I) ELISA results for α-mannan–induced cytokine production in supernatants of BMDCs with flumatinib mesylate pretreatment (H) or knockdown of murine c-Abl (I). (J and K) Immunoblotting analysis of α-mannan–induced phosphorylation of c-Cbl (J) or degradation of RelB (K) in BMDCs with c-Abl agonist (DPH) pretreatment. (L to N) Weight loss (L), colon length (M), and histological analysis (N) of DSS (2.5%)–treated wild-type mice (n = 6 for each group), which were intraperitoneally administrated with vehicle or DPH (70 mg/kg) every day. Bar graphs show means ± SEM. *P < 0.05 and **P < 0.01. Photo credit: Jie-Lin Duan, Tongji University.